JP2013529687A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529687A5
JP2013529687A5 JP2013518575A JP2013518575A JP2013529687A5 JP 2013529687 A5 JP2013529687 A5 JP 2013529687A5 JP 2013518575 A JP2013518575 A JP 2013518575A JP 2013518575 A JP2013518575 A JP 2013518575A JP 2013529687 A5 JP2013529687 A5 JP 2013529687A5
Authority
JP
Japan
Prior art keywords
compound
formula
item
solvent
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518575A
Other languages
English (en)
Japanese (ja)
Other versions
JP5923499B2 (ja
JP2013529687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042169 external-priority patent/WO2012012139A1/en
Publication of JP2013529687A publication Critical patent/JP2013529687A/ja
Publication of JP2013529687A5 publication Critical patent/JP2013529687A5/ja
Application granted granted Critical
Publication of JP5923499B2 publication Critical patent/JP5923499B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518575A 2010-06-30 2011-06-28 キナーゼインヒビターの合成および使用 Expired - Fee Related JP5923499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
US61/359,942 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013529687A JP2013529687A (ja) 2013-07-22
JP2013529687A5 true JP2013529687A5 (cg-RX-API-DMAC7.html) 2014-08-14
JP5923499B2 JP5923499B2 (ja) 2016-05-24

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518575A Expired - Fee Related JP5923499B2 (ja) 2010-06-30 2011-06-28 キナーゼインヒビターの合成および使用

Country Status (10)

Country Link
US (1) US9505719B2 (cg-RX-API-DMAC7.html)
EP (1) EP2588476A4 (cg-RX-API-DMAC7.html)
JP (1) JP5923499B2 (cg-RX-API-DMAC7.html)
CN (1) CN103168037A (cg-RX-API-DMAC7.html)
AU (1) AU2011280031B2 (cg-RX-API-DMAC7.html)
CA (1) CA2803005A1 (cg-RX-API-DMAC7.html)
MX (1) MX343894B (cg-RX-API-DMAC7.html)
NZ (1) NZ604801A (cg-RX-API-DMAC7.html)
WO (1) WO2012012139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300012B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
WO2026086879A1 (zh) * 2024-10-25 2026-04-30 应世生物科技(南京)有限公司 Fak抑制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0114814A (pt) 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CA2626579A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
BRPI0715423A2 (pt) 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
EP2464642A4 (en) 2009-08-12 2013-01-09 Poniard Pharmaceuticals Inc PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Similar Documents

Publication Publication Date Title
CA2950300C (en) Synthesis of polycyclic-carbamoylpyridone compounds
CA3080138A1 (en) Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
JP6269508B2 (ja) 精製されたアミン化合物の製造方法
JPWO2014157612A1 (ja) (1s,4s,5s)−4−ブロモ−6−オキサビシクロ[3.2.1]オクタン−7−オンの製造方法
RU2621725C2 (ru) Способ получения 1-([1,3]диоксолан-4-илметил)-1н-пиразол-3-иламина
US10189760B2 (en) Method for preparing sitagliptin intermediate via asymmetrical reduction method
JP2010532357A (ja) 1,2−置換3,4−ジオキソ−1−シクロブテン化合物における制御された結晶サイズのための方法
JP6228210B2 (ja) フルボキサミン遊離塩基の精製方法およびそれを用いた高純度フルボキサミンマレイン酸塩の製造方法
CN102617542A (zh) 一种奥美沙坦中间体的制备方法及纯化方法
CN103443084A (zh) 制备苯达莫司汀的方法
CN115175913A (zh) 取代的双三环化合物及其药物组合物和用途
JP5923499B2 (ja) キナーゼインヒビターの合成および使用
EP3227312A1 (en) A process for purification of carfilzomib
JP6947354B2 (ja) リナグリプチンの製造法
JP2008201740A (ja) エダラボンの精製方法及び高純度エダラボン
JP6951418B2 (ja) 抗hcmvウイルス化合物
AU2021260048B2 (en) Antiviral 1,3-di-oxo-indene compounds
CN105017063B (zh) 5-氨基-2,4,6-三碘间苯二甲酸衍生物及其盐、水合物或溶剂化物
US10131674B2 (en) Process for preparing Substituted Indole Compounds
CN108586450B (zh) 一种胆碱m受体抗结剂的重结晶纯化方法
CN107739328B (zh) 用于合成巴瑞替尼的关键中间体1的制备方法
CN103755624B (zh) 一种哌啶衍生物的合成方法
JP5397706B2 (ja) 高純度1−ベンジル−3−アミノピロリジンの製造方法
CN103772425B (zh) 硅杂哌啶衍生物及其制备方法与用途
CN110143947B (zh) 一种色瑞替尼类似物的制备方法